NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Tuesday, July, 30th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.05 by $0.02. The medical research company had revenue of $101.71 million for the quarter, compared to analysts' expectations of $97.32 million. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The firm's revenue for the quarter was up 50.1% compared to the same quarter last year. During the same period last year, the company earned $0.05 EPS. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NeoGenomics issued an update on its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $0.23-0.27 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $388-402 million, compared to the consensus revenue estimate of $393.32 million.

7 brokers have issued 1-year price targets for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they expect NeoGenomics' share price to reach $24.57 in the next twelve months. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

Media headlines about NEO stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. NeoGenomics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 5,500,000 shares, an increase of 13.2% from the August 30th total of 4,860,000 shares. Based on an average daily volume of 863,900 shares, the days-to-cover ratio is currently 6.4 days. Currently, 5.6% of the shares of the stock are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Teva Pharmaceutical Industries (TEVA), Eurofins Scientific (ERFSF), Bausch Health Companies (BHC), ABIOMED (ABMD), Ionis Pharmaceuticals (IONS), Avantor (AVTR), Masimo (MASI), Icon (ICLR), Novocure (NVCR), BIO-TECHNE (TECH), Molina Healthcare (MOH), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT) and Recordati (RCDTF).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Netflix (NFLX), Amarin (AMRN), Exelixis (EXEL), Intel (INTC) and AT&T (T).

NeoGenomics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.35%), State of Alaska Department of Revenue (0.08%), Robeco Institutional Asset Management B.V. (0.08%), CIBC Private Wealth Group LLC (0.07%), Envestnet Asset Management Inc. (0.04%) and Stephens Inc. AR (0.03%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Stephens Inc. AR and CIBC Private Wealth Group LLC. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, HMS Capital Management LLC, Summit Creek Advisors LLC, Juncture Wealth Strategies LLC, Campbell & CO Investment Adviser LLC, Fox Run Management L.L.C., Nisa Investment Advisors LLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $20.25.

NeoGenomics has a market capitalization of $2.10 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]